Menopausal hormone therapy for the primary prevention of chronic conditions: A systematic review to update the U.S. preventive services task force recommendations

Annals of Internal Medicine

Volumn 157, Issue 2, 2012, Pages 157-

  Nelson, Heidi D ^a   Walker, Miranda ^a   Zakher, Bernadette ^a   Mitchell, Jennifer ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE;

BREAST CANCER; CHRONIC DISEASE; COGNITIVE DEFECT; DEEP VEIN THROMBOSIS; DEMENTIA; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; FEMALE; FRACTURE; GALLBLADDER DISEASE; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LUNG CANCER; LUNG EMBOLISM; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URINE INCONTINENCE;

EID: 84863973283     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-157-2-201207170-00466     Document Type: Review

References (64)

1. U.S. Food and Drug Administration. Estrogen and Estrogen with Progestin Therapies for Postmenopausal Women. Silver Spring, MD: U.S. Food and Drug Administration; 2010. Accessed at www.fda.gov/Drugs/DrugSafety/Information byDrugClass/ucm135318.htm on 8 May 2012.
2. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-12. [PMID: 15082697]
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-33. [PMID: 12117397]
4. U.S. Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med. 2002;137:834-9. [PMID: 12435221]
5. U.S. Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force. Ann Intern Med. 2005;142:855-60. [PMID: 15897536]
6. Canadian Task Force on Preventive Health Care. Hormone Replacement Therapy for the Primary Prevention of Chronic Diseases. Ottawa, Canada: Canadian Task Force on Preventive Health Care; 2004. Accessed at www.canadiantaskforce.ca /recommendations/2003_01_eng.html on 8 May 2012.
7. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the american heart association. Circulation. 2011;123:1243-62. [PMID: 21325087]
8. American Academy of Family Physicians. Hormone Replacement Therapy. Leawood, KS: American Academy of Family Physicians; 2005. Accessed at www.aafp.org/online/en/home/clinical/exam/hormonereplacement.html on 8 May 2012.
9. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012;19: 257-71. [PMID: 22367731]
10. American College of Obstetricians and Gynecologists, Women's Health Care Physicians. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 50, January 2003. Obstet Gynecol. 2004; 103:203-16. [PMID: 14704265]
11. Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: Systematic Review to Update the 2002 and 2005 U.S. Preventive Services Task Force Recommendations. Contract HHSA-290-2007-10057-1-EPC3, task order 3. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
12. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288:872-81. [PMID: 12186605]
13. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al; Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21-35. [PMID: 11306229]
14. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, et al; Women's Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA. 2003;290:1739-48. [PMID: 14519708]
15. Bonds DE, Lasser N, Qi L, Brzyski R, Caan B, Heiss G, et al. The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial. Diabetologia. 2006;49:459-68. [PMID: 16440209]
16. Brunner RL, Gass M, Aragaki A, Hays J, Granek I, Woods N, et al; Women's Health Initiative Investigators. Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial. Arch Intern Med. 2005;165:1976-86. [PMID: 16186467]
17. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al; Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003;290:1729-38. [PMID: 14519707]
18. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, et al; WHI Investigators. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304:1684-92. [PMID: 20959578]
19. Chlebowski RT, Anderson GL, Manson JE, Schwartz AG, Wakelee H, Gass M, et al. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J Natl Cancer Inst. 2010; 102:1413-21. [PMID: 20709992]
20. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al; WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289:3243-53. [PMID: 12824205]
21. Chlebowski RT, Schwartz AG, Wakelee H, Anderson GL, Stefanick ML, Manson JE, et al; Women's Health Initiative Investigators. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet. 2009;374: 1243-51. [PMID: 19767090]
22. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, et al; Women's Health Initiative Investigators. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350:991-1004. [PMID: 14999111]
23. Cirillo DJ, Wallace RB, Rodabough RJ, Greenland P, LaCroix AZ, Limacher MC, et al. Effect of estrogen therapy on gallbladder disease. JAMA. 2005; 293:330-9. [PMID: 15657326]
24. Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med. 2006;166:772-80. [PMID: 16606815]
25. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al; Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA. 2004;292:1573-80. [PMID: 15467059]
26. Gramling R, Eaton CB, Rothman KJ, Cabral H, Silliman RA, Lash TL. Hormone replacement therapy, family history, and breast cancer risk among postmenopausal women. Epidemiology. 2009;20:752-6. [PMID: 19451819]
27. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, et al; Women's Health Initiative Investigators. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003;348:1839-54. [PMID: 12642637]
28. Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, et al; WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008;299:1036-45. [PMID: 18319414]
29. Hendrix SL. The Women's Health Initiative estrogen plus progestin trial: the study and how it changes our practice. J Am Osteopath Assoc. 2003;103:S3-5. [PMID: 12625631]
30. Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, Iglesia C, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005;293:935-48. [PMID: 15728164]
31. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, et al; WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation. 2006;113:2425-34. [PMID: 16702472]
32. Hsia J, Criqui MH, Rodabough RJ, Langer RD, Resnick HE, Phillips LS, et al; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of peripheral arterial disease: the Women's Health Initiative. Circulation. 2004;109:620-6. [PMID: 14769684]
33. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, et al; Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med. 2006;166: 357-65. [PMID: 16476878]
34. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, et al; WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305:1305-14. [PMID: 21467283]
35. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-34. [PMID: 12904517]
36. Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C, et al; Women's Health Initiative Investigators. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia. 2004;47:1175-87. [PMID: 15252707]
37. Ritenbaugh C, Stanford JL, Wu L, Shikany JM, Schoen RE, Stefanick ML, et al; Women's Health Initiative Investigators. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2008;17:2609-18. [PMID: 18829444]
38. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465-77. [PMID: 17405972]
39. Toh S, Hernández-Di{dotless}́az S, Logan R, Rossouw JE, Hernán MA. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med. 2010;152:211-7. [PMID: 20157135]
40. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, et al; WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003;289:2673-84. [PMID: 12771114]
41. Culhane NS. Estrogen plus progestin may increase incidence of dementia. J Fam Pract. 2003;52:754-5. [PMID: 14529594]
42. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, et al; Women's Health Initiative Memory Study. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291:2959-68. [PMID: 15213207]
43. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, et al; WHIMS Investigators. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2663-72. [PMID: 12771113]
44. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al; Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291: 2947-58. [PMID: 15213206]
45. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, et al; WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651-62. [PMID: 12771112]
46. Espeland MA, Brunner RL, Hogan PE, Rapp SR, Coker LH, Legault C, et al; Women's Health Initiative Study of Cognitive Aging Study Group. Longterm effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women's Health Initiative study of cognitive aging extension. J Am Geriatr Soc. 2010;58:1263-71. [PMID: 20649689]
47. Resnick SM, Espeland MA, An Y, Maki PM, Coker LH, Jackson R, et al; Women's Health Initiative Study of Cognitive Aging Investigators. Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. J Clin Endocrinol Metab. 2009;94:4152-61. [PMID: 19850684]
48. Resnick SM, Maki PM, Rapp SR, Espeland MA, Brunner R, Coker LH, et al; Women's Health Initiative Study of Cognitive Aging Investigators. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab. 2006;91:1802-10. [PMID: 16522699]
49. Tierney MC, Oh P, Moineddin R, Greenblatt EM, Snow WG, Fisher RH, et al. A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women. Psychoneuroendocrinology. 2009;34:1065-74. [PMID: 19297102]
50. Grady D, Applegate W, Bush T, Furberg C, Riggs B, Hulley SB. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Control Clin Trials. 1998;19:314-35. [PMID: 9683309]
51. Grady D, Yaffe K, Kristof M, Lin F, Richards C, Barrett-Connor E. Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study. Am J Med. 2002;113:543-8. [PMID: 12459399]
52. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al; HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49-57. [PMID: 12090862]
53. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, et al; HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:58-66. [PMID: 12090863]
54. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-13. [PMID: 9718051]
55. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, et al; Heart and Estrogen/progestin Replacement Study. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138:1-9. [PMID: 12513038]
56. Steinauer JE, Waetjen LE, Vittinghoff E, Subak LL, Hulley SB, Grady D, et al. Postmenopausal hormone therapy: does it cause incontinence? Obstet Gynecol. 2005;106:940-5. [PMID: 16260510]
57. Cherry N, Gilmour K, Hannaford P, Heagerty A, Khan MA, Kitchener H, et al; ESPRIT team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet. 2002;360: 2001-8. [PMID: 12504395]
58. Ettinger B, Ensrud KE, Wallace R, Johnson KC, Cummings SR, Yankov V, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol. 2004;104:443-51. [PMID: 15339752]
59. Johnson SR, Ettinger B, Macer JL, Ensrud KE, Quan J, Grady D. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet Gynecol. 2005;105:779-87. [PMID: 15802405]
60. Waetjen LE, Brown JS, Vittinghoff E, Ensrud KE, Pinkerton J, Wallace R, et al. The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women. Obstet Gynecol. 2005;106:946-52. [PMID: 16260511]
61. Yaffe K, Vittinghoff E, Ensrud KE, Johnson KC, Diem S, Hanes V, et al. Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life. Arch Neurol. 2006;63:945-50. [PMID: 16831962]
62. Vickers MR, Martin J, Meade TW; WISDOM study team. The Women's international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial. BMC Womens Health. 2007;7:2. [PMID: 17324282]
63. Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012; 13:476-86. [PMID: 22401913]
64. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998; 19:61-109. [PMID: 9492970]